In February 2015 I started working as an editor at Skipr. At that time, Zorgvisie was still the main competitor. Since 2019, we’ve been producing these two titles and Qruxx, our platform around value-based care, with one editor. I continue to write with great interest about Dutch healthcare regulation, from real estate and financing to the interests of patients and healthcare staff. In addition, I am now the Deputy Editor-in-Chief. I am proud to play a pivotal role in the well-oiled machine that our editorial team represents.
With an emphasis on proper care, questions arise about the proven efficacy of medications and treatments. Answering these questions is complex, but it becomes even more difficult with public opinion that leaves no room for doubt. Sarah Kleinen and Wim Goettsch of the National Institute of Health Care note this.
excellent
Last month they were both
“Twitter junkie. Lifelong communicator. Award-winning analyst. Subtly charming internetaholic.”